Orthocell was featured in a Stockhead article by leading biotech journalist Tim Boreham titled “Orthocell flags rapid ‘hockey stick’ revenue growth in the US$1.6 billion US nerve repair market.”
The article explores our global expansion, including the rapid rollout of Remplir in the US following FDA clearance, new international markets such as Canada and Asia, and emerging opportunities in prostate surgery. It also highlights the Company’s strong financial position as we scale globally.
Here’s an excerpt:
“Van Der Wielen notes Orthocell’s revenue has grown at an average annual compound rate of 34% over the past three years. The company is “not too far from heading to profit” as US revenues flow in.
“We are at an inflexion point,” Van Der Wielen says. “We expect to see revenue rates sustainably increase. We are very much focused on the US and couldn’t be happier with the progress and the quality of people we already have employed.”